Home Journals Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Credits to the Source Link Daniel
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Footnotes

Funding information: These studies were sponsored by Pfizer Inc. Funding for medical writing support was provided by Pfizer Inc.

Disclosures: J-FC has acted as a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Janssen, MedImmune, Merck & Co., Nextbiotix, Novartis, Otsuka Pharmaceutical Development & Commercialization, Inc., Pfizer Inc, Protagonist, Second Genome, Seres Therapeutics, Shire, Takeda, and Theradiag; he has received financial support for research from AbbVie, Intestinal Biotech Development, and Janssen and Janssen; and he has participated in speakers’ bureaus for AbbVie, Celgene, Ferring Pharmaceuticals, Genfit, and Takeda. MTO has acted as an advisory board member for AbbVie, Elan, Janssen, Lycera, Merck & Co., Pfizer Inc, Takeda, and UCB. AJT, LS, CIN, HZ, NL, GSF, DQ, and CS are employees and stockholders of Pfizer Inc. WR has acted as a consultant for 4SC, Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cellerix, Celltrion, Centocor, ChemoCentryx, Covance, Danone Austria, Elan, Eli Lilly, Ernst & Young, Falk Pharma GMbH, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, MedAhead, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestlé, Novartis, Ocera, Otsuka, Parexel, PDL, Pfizer Inc, Pharmacosmos, Philip Morris Institute, Proctor & Gamble, Prometheus Laboratories, Protagonist, Provention, Robarts Clinical Trials, Roland Berger GmBH, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, SetPoint Medical, Sigmoid, Takeda, Therakos, TiGenix, UCB, Vifor, Zealand, and Zyngenia; he has participated in speakers’ bureaus for Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Celltrion, Centocor, Danone Austria, Elan, Falk Pharma GMbH, Ferring Pharmaceuticals, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; he has received financial support for research from Abbott Laboratories, AbbVie, Aesca, Centocor, Falk Pharma GMbH, Immundiagnostik, and MSD; and he has acted as an advisory board member for 4SC, Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cellerix, Celltrion, Centocor, ChemoCentryx, Danone Austria, Elan, Ferring Pharmaceuticals, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestlé, Novartis, Ocera, Otsuka, PDL, Pfizer Inc, Pharmacosmos, Proctor & Gamble, Prometheus Laboratories, Sandoz, Schering-Plough, Second Genome, SetPoint Medical, Takeda, Therakos, TiGenix, UCB, Zealand, and Zyngenia.

Writing assistance: Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

Author contributions: WR was an investigator on the trials included in this analysis and made substantial contributions to the interpretation of the data. J-FC, MTO, AJT, LS, CIN, HZ, NL, GSF, DQ, and CS contributed to the design of the analysis and interpreted the data. All authors contributed to the drafting of the manuscript, and critically reviewed/revised the manuscript for important intellectual content. All authors approved the final version of the manuscript before submission.

Conference presentations: Data in this manuscript have been presented at Advances in Inflammatory Bowel Disease (AIBD; November 2017), United European Gastroenterology Week (UEG Week; October 2018 and October 2019), and the American College of Gastroenterology Annual Meeting (ACG; October 2018 and October 2019).

Source Link

Related Articles

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: